Mixed lineage leukemia: roles in human malignancies and potential therapy.
about
Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitorsOverexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cellsRegistered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemiaDownregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human.Mixed lineage leukemia: a structure-function perspective of the MLL1 protein.Transcriptional regulation and its misregulation in disease.Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation.CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.MLL1 promotes cervical carcinoma cell tumorigenesis and metastasis through interaction with β-catenin.Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing.The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.MLL-SEPTIN gene fusions in hematological malignancies.Menin as a hub controlling mixed lineage leukemia.Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Epigenetic alterations in acute myeloid leukemias.MLL leukemia and future treatment strategies.The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.The importin-alpha/nucleophosmin switch controls taspase1 protease function.Cell-based analysis of structure-function activity of threonine aspartase 1AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3GAS41 amplification results in overexpression of a new spindle pole proteinEpigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation.The identification of transcription factors expressed in the notochord of Ciona intestinalis adds new potential players to the brachyury gene regulatory networkMixed lineage leukaemia-4 regulates cell-cycle progression and cell viability and its depletion suppresses growth of xenografted tumour in vivo.Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy.Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL.TOP3A, a new partner gene fused to MLL in an adult patient with de novo acute myeloid leukaemia
P2860
Q28478269-AA0E0355-375E-461A-9F50-6A95744CB5D4Q28483263-3F95EB16-0310-499D-A2A5-B1AFA72815C9Q28608331-3AF8431D-04E6-4EFD-AB28-67AD4A2F0916Q33794291-7161B6C2-0EFD-4607-B308-AA4715F1044BQ33862548-1720E7F1-321D-41E3-B0C6-D7C2A630B84EQ33943731-73197D49-00A4-4F28-9BD5-53819A229B44Q34036033-C1EF2B27-8C5B-4CFF-9E7B-17F4AEF8C98BQ34199816-2EDF8C1E-047E-456B-9AA0-27A2096CD1EEQ34581540-22F58203-3B1B-4D65-87DD-8041BBEDAE11Q35963779-4BDD7DD3-D79D-478C-AC9A-441297A7F57BQ36056038-F5217FC9-AB94-4BC3-82D6-22FFC1D02A0BQ36061440-8550B788-CA52-4CF9-98B5-C70EB6E9D4B6Q36713389-624C9564-E8D6-43B2-881D-249DEE01ECD1Q37397989-B3CA239A-F3F3-47D0-9571-40A3B1018043Q37710711-E9AABB3B-E1FD-4F27-84FB-7029DDF293C4Q37874929-FB129353-385F-4FE2-B30E-99B6414D5A14Q37895709-4B3E12CB-574A-4206-B8F2-13BFB1054102Q38029260-9B695132-333B-450D-AC60-5A77C88359F8Q38161393-9AAEB0D8-6919-44D1-A8FE-03E1306F1A58Q38264968-0C86EE7F-A720-49B0-BE7E-BC3A700EB277Q38367735-AC32D265-3E96-49E0-B364-0E24B15CD035Q39044567-3972A62F-8D8C-4B38-B6D1-07E5076B21BDQ39574027-59CCD96D-D237-4FC8-AA70-425A0D6B1CF1Q39630613-FDCDB1C2-DDC0-4BA1-A6E5-0362D62006A0Q41546163-7CBFDCE0-BEDC-4FAE-91E9-3148268C8433Q41855172-38512816-E0DD-49D9-A659-8C97E4B38312Q41997152-8344C901-E010-49E9-8950-4393EA5D63A6Q42164448-769BA3B2-6435-460F-A7E1-7767410EB72CQ42234071-868020DA-0FC4-43E7-BE76-47112A163405Q42325896-DB8786DB-89A4-4A56-9A16-A6EA438B9D50Q42536195-7A46C0A7-92AC-43D5-A7D6-5E334E3AD34CQ58492915-EB26F9BC-98C7-4148-867F-78D1280879C3
P2860
Mixed lineage leukemia: roles in human malignancies and potential therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@en
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@nl
type
label
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@en
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@nl
prefLabel
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@en
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@nl
P2860
P1433
P1476
Mixed lineage leukemia: roles in human malignancies and potential therapy.
@en
P2093
Rolf Marschalek
P2860
P304
P356
10.1111/J.1742-4658.2010.07608.X
P407
P577
2010-03-04T00:00:00Z